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Summary. Inclusion of the BCR±ABL ES probe in routine
cytogenetics led to the identification of a subgroup of
Philadelphia positive (Ph1) chronic myeloid leukaemia
patients characterized by a 5 0-ABL deletion. This anomaly
was observed in 5/51 cases (9´8%). Cytological and clinical
data suggest that the 5 0-ABL deletion may be associated
with dysplastic features of polymorphonuclear cells and
metamyelocytes and a short chronic phase duration.
Keywords: chronic myeloid leukaemia, Philadelphia chro-
mosome, BCR±ABL positive, 5 0-ABL deletion, FISH.
Bone marrow cells of 90±95% of chronic myeloid leukaemia
(CML) patients harbour the Philadelphia chromosome,
which results from the translocation t(9;22)(q34;q11)
(Rowley, 1973). At the molecular level, the translocation
juxtaposes 3 0 DNA sequences of the ABL oncogene mapping
on 9q34.1 with 5 0 DNA sequences of the BCR gene located
on 22q11, giving rise to a chimaeric BCR±ABL fusion gene
on the derivative 22 (Melo, 1996).
New fluorescence in situ hybridization (FISH) strategies
are now available that are highly sensitive to detect the
BCR±ABL fusion gene on interphase nuclei (Bentz et al,
1994; Sinclair et al, 1997; Buno et al, 1998). In this context,
the LSI BCR±ABL ES (extra signal) dual-colour transloca-
tion probe was introduced by Vysis (Downer's Grove, IL,
USA) in 1998. In this novel system, the ABL probe (650 kb)
spans both sides of the breakpoint on 9q so that Ph1 cells
show (i) co-localization of the BCR and ABL probes and (ii)
the presence of a third independent fluorescent signal for
ABL (split signal remaining on the derivative 9). Using this
new system, we observed a deletion of the 5 0-ABL region in
5/51 Ph1 patients. We report here the clinical and
cytogenetic findings for these five patients.
MATERIALS AND METHODS
Fifty-one consecutive patients were included in the study:
31 men and 20 women, aged 26±84 years (median
54´5 years). All patients were studied at diagnosis, before
any therapy. The diagnosis of CML was based on typical
peripheral blood findings and the presence of the Phila-
delphia chromosome in marrow cells. The patients were
re-evaluated with the new LSI BCR±ABL ES probe. Five
hundred nuclei/patients were analysed.
RESULTS
Although the expected signals for the BCR±ABL ES probe
were observed in Ph1 cells from 46/51 cases, the remaining
five patients (9´8%) showed an atypical hybridization
pattern that resulted from the loss of the split ABL signal
normally present on the derivative 9, which is consistent
with a deletion of the 5 0-ABL region (Fig 1A and B). The
clinical and cytogenetic data for these five patients are
summarized in Table I. Interestingly, they presented with
similar cytological features, including (i) small and mono-
lobulated megakaryocytes (4/5 patients); (ii) polymorpho-
nuclear cells and metamyelocytes with clumped chromatin
(4/5 patients); (iii) Pelger-HueÈt or Pelger-HueÈt-like anoma-
lies (3/5 patients) (P , 0´025); and (iv) dysgranulopoiesis
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including hypogranular and agranular elements (3/5
patients) (Table I). Two patients presented with the four
cytological features (P , 0´001).
Patients 1, 4 and 5 underwent bone marrow transplanta-
tion (BMT) in chronic phase (Table I). Patient 2 developed
an acceleration phase (AP) and a blast crisis (BC) 16 and
25 months, respectively, after diagnosis. An extra Ph
chromosome was observed during acceleration and blast
crisis in, respectively, 4% and 6% of the metaphases. He
underwent BMT 29 months after diagnosis but died from
neural infection. Patient 3 presented with acute myeloid
leukaemia and 65% circulating blasts 9 months after
diagnosis. No cytogenetic analysis was performed at that
time. She died 3 months later.
DISCUSSION
Screening of CML patients with the BCR±ABL ES probe
(Vysis) led to the identification of a subgroup of patients
with a 5 0-ABL deletion, including the arginosuccinate
synthetase gene. In our series, 5/51 patients (9´8%) showed
both the BCR±ABL rearrangement and the 5 0-ABL deletion.
Similar observations have been reported by Dewald et al
(1998, 1999) with the D-FISH probe from Oncor. They
observed atypical hybridization patterns consistent with loss
of 3 0-BCR, loss of 5 0-ABL or loss of both segments in 28/141
(19%) Ph1 CML patients (Dewald et al, 1999). More
particularly, the 5 0-ABL segment was lost in 17/141 (12%)
patients.
However, it remains to be determined whether the 5 0-ABL
deletion is to be considered as a secondary chromosomal
change, heralding the evolution towards an acceleration
phase (AP) or blast crisis (BC), or whether the deletion
characterizes a subset of CML patients at diagnosis. In the
light of our results, we cannot favour either of these two
hypotheses. On the one hand, the FISH data indicated that
the translocation and the deletion appeared in a one-step
event as we were unable to detect a subclone with the
expected hybridization pattern. On the other hand, patients
with both the translocation and the submicroscopic deletion
seemed to have particular cytological features associated
with a short chronic phase duration. In our series, the
mean duration of chronic phase for the two patients
that developed an AP and/or BC was 12´5 months (9±
16 months). This interval is markedly shorter than the
mean duration of chronic phase (30±60 months) reported
in the literature (Sawyers, 1999). The possible prognostic
significance of the 5 0-ABL deletion was also noted in the
study of Dewald et al (1998), in which atypical hybridization
patterns were observed in patients with masked Ph (five
patients) or with additional chromosomal changes char-
acteristic of the AP or BC phases (two patients). However,
the observation of an extra Ph during AP and BC in one of
our patient indicates that the 5 0-ABL deletion is probably
not directly involved in acceleration or blast crisis. Neverthe-
less, the deletion could favour the emergence of additional
chromosomal anomalies, the mechanism of which remains
to be elucidated.
Table I. Clinical and cytogenetic data of patients with both the translocation and the 5 0-ABL deletion.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex Male Male Female Male Female
Age (years) 44 51 84 53 38
Haematocrit (%) 42 41´2 32´8 34´8 34´5
Platelets (109/l) 516 341 617 214 368
White blood cell count (109/l) 188 78´8 151 343 168
Blasts (%) 2´5 2 1 0´6 1´6
Splenomegaly (cm) 4 3 ± 9 23
Sokal index 0´81 0´82 1´17 0´97 1´46
Ph chromosome (% metaphase) 100 100 100 100 100
FISH
Expected pattern 0´35 0´25 0´2 0´3 0´3
Co-localization pattern 93´6 86´2 94´5 97´5 95´4
Disease stage Chronic phase Chronic phase Chronic phase Chronic phase Chronic phase
Treatment Hydrea, IFN-a Myleran, IFN-a Hydrea Hydrea ARA-C, IFN-a, Hydrea
Small monolobulated megakaryocytes ± 1 1 1 1
Clumped chromatin in neutrophils 1 1 1 1 ±
Pelger- HueÈt anomaly ± 1 1 1 ±
Hypogranular/agranular neutrophils ± ± 1 1 1
BMT 1 1 ± 1 1
Delay from diagnosis (months) 22 29 ± 8 13
Duration of chronic phase (months) ± 16 9 ± ±
Survival (months) 48* 45 10 22* 14*
Cause of death ± Infectious disease AML ± ±
*Still alive. IFN-a, a-interferon. ARA-C, cytarabine.
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In conclusion, the use of the new commercially available
probes (BCR±ABL ES and D-FISH) could enable the
subclassification of CML patients according to the presence
of 5 0-ABL and/or 3 0-BCR deletions. Our results indicate that
about 10% of CML patients have the 5 0-ABL deletion,
particular cytological features and a possible short chronic
phase duration. However, our series is small and collection
of large cohorts of patients is needed to assess these clinical
findings.
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NOTE ADDED IN PROOF
During submission of this manuscript, Sinclair et al
published a cohort of 16 patients with deletions of the 5 0-
ABL region. They showed that these deletions identify a
subgroup of CML patients that have a poor prognosis
compared with classical Ph1 CML patients [Sinclair, P.B.,
Nacheva, E.P., Leversha, M., Telford, N., Chang, J., Reid, A.,
Bench, A., Champion, K., Huntly, B. & Green, A.R. (2000).
Large deletions at the (9;22) breakpoint are common and
may identify a poor-prognosis subgroup of patients with
chronic myeloid leukaemia. Blood, 95, 738±744].
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Fig 1. (A) In Ph1 nuclei and metaphases, the expected hybridiza-
tion pattern consists of one green (BCR on chromosome 22), two
orange (normal and split ABL on normal and derivative 9) and one
yellow (fused BCR/split ABL on derivative 22) signals. (B) The split
ABL signal on derivative 9 (arrow) is missing in patients with the
atypical hybridization pattern.
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